Treatment differences at high volume centers and low volume centers in non-metastatic and metastatic adrenocortical carcinoma

Am J Surg. 2022 Mar;223(3):582-586. doi: 10.1016/j.amjsurg.2022.01.004. Epub 2022 Jan 20.

Abstract

Background: Adrenocortical carcinoma (ACC) is rare with poor survival. Do treatment and outcomes vary by volume?

Methods: NCDB (2004-2017) was searched for patients with ACC. High-volume centers (HVCs) were defined by ≥ 15 ACC and low-volume centers by ≤ 7 total cases. Multivariable Cox and logistic regression analysis were performed.

Results: ACC patients at HVCs were significantly more likely to have surgery, chemotherapy, and had lower 90-day readmission. HVCs were significantly more likely than LVCs to administer chemotherapy to surgical NonMetastatic (NM)-ACC patients. There was no significant difference in overall survival (OS), 90-day mortality, length of stay, or radiation treatments between the two. Operative Metastatic (M)-ACC at HVC had significantly improved OS, more chemotherapy administered, and lower 90-day mortality.

Conclusion: NM-ACC and M-ACC treated at HVCs were more likely to have surgery and multimodality therapy. NM-ACC having surgery at HVCs and LVCs had similar OS. M-ACC at HVCs had improved OS and 90-day mortality.

Keywords: Adrenocortical carcinoma; High volume center; Low volume center; Overall survival.

MeSH terms

  • Adrenal Cortex Neoplasms* / therapy
  • Adrenocortical Carcinoma* / surgery
  • Combined Modality Therapy
  • Hospitals, High-Volume
  • Humans
  • Length of Stay
  • Retrospective Studies